South Rampart Pharma aims to advance the safe treatment of pain by developing new small-molecule solutions that have the potential to overcome many risks associated with current pain medicines. South Rampart Pharma’s lead compounds have been effective in reducing both pain and fever in preclinical studies without the liver and kidney toxicity associated with current non-opioid analgesics. As a new small molecule treatment option that is not a biologic therapy, South Rampart Pharma’s compounds have great potential as a value product that will be low cost and accessible to many patients.
Leadership Team & Collaborations
HERNAN A. BAZAN
MD, DFSVS, FACS
NICOLAS G. BAZAN
Boyd Professor of Neurology, Ophthalmology, Biochemistry and Molecular Biology
Director, Neuroscience Center of Excellence
LSUHSC School of Medicine